Never Say Never: Digoxin, William Withering, and the Changing Certainties of Cardiology

In a long cardiology career, one remembers not only drugs but slogans. Few therapies have lived through more reversals than digitalis: first as a breakthrough, then as habit, then as controversy, then almost as an embarrassment, and now again as a subject of serious reconsideration. The lesson is not merely about one old drug. It is about how medicine repeatedly confuses fashion with truth, and how often certainty must be revised when physiology, evidence, and clinical context are brought back into the same frame. 

The story properly begins with William Withering, whose 1785 account of foxglove transformed a traditional remedy into a recognizable medical therapy. He did more than “discover” a plant effect; he observed, classified, and disciplined its use, linking clinical benefit with careful dosing and warning against toxicity. In that sense, the digoxin story began not with therapeutic bravado but with clinical humility: an effective medicine, yes, but one requiring judgment.[

For generations after Withering, digitalis became one of the very few agents that seemed genuinely useful in patients with dropsy and failing hearts. Long before randomized trials, biomarkers, or ejection fraction categories, physicians valued what they could see at the bedside: less congestion, easier breathing, slower pulse, and sometimes unmistakable symptomatic relief. That is why digitalis became woven into ordinary medical practice. It was not a niche drug; for much of cardiology’s earlier life, it was close to a default language of treatment.

By the twentieth century, that broad acceptance had hardened into routine. Digitalis was used widely not because every mechanism was understood and not because anyone had proven that it prolonged life, but because medicine still accepted symptomatic and hemodynamic improvement as meaningful clinical achievements. In that era, the central question was less “Should we use digitalis?” than “How do we use it safely?”

Then came the era of intensity. In some settings, the logic of practice drifted toward digitalization, loading, and serum exposures uncomfortably close to toxicity. A drug with real physiologic effects and a narrow therapeutic window invited both success and overconfidence. But the real historical turning point was not toxicity alone. It was that the therapeutic world around digitalis changed. As newer agents emerged — first vasodilator and neurohormonal approaches, then ACE inhibitors, beta-blockers, mineralocorticoid antagonists, and later SGLT2 inhibitors — heart failure treatment was gradually reorganized around disease modification and survival benefit rather than hemodynamic support alone 

This did not immediately erase digoxin. In fact, the transition was more complicated. Even after newer therapies began to displace cardiac glycosides from center stage, digoxin retained a practical role because many clinicians still saw benefits in symptoms, rate control, and prevention of worsening heart failure. The DIG trial crystallized this ambiguity. It showed no mortality benefit, yet it did show fewer hospitalizations for heart failure. In another era, that might have preserved the drug’s reputation. But by the late twentieth century, mortality had become the gold-standard endpoint, and a therapy that failed to prolong life now looked diminished, even if it helped keep patients out of the hospital.

There was, however, an important intermediate phase that should not be lost. Digoxin was not simply pushed aside and forgotten. Withdrawal trials such as PROVED and RADIANCE showed that stable heart failure patients often worsened when digoxin was stopped, which argued against the idea that the drug had become clinically irrelevant. Later analyses also suggested that lower serum digoxin concentrations were associated with better outcomes than higher ones, helping to shape a more careful low-dose philosophy. For a time, this amounted to a partial rehabilitation: not exactly “digoxin for all,” but certainly a renewed belief that low-dose digoxin still had a meaningful place for many patients when used thoughtfully. 

Yet this return proved fragile. Observational studies increasingly reported higher mortality among patients receiving digoxin, and in a culture already moving toward therapies with stronger mortality credentials, these reports carried great influence. Later critiques made a crucial point: observational data and randomized trial data were not telling the same story, and much of the apparent harm likely reflected confounding by indication, because sicker patients were more likely to receive digoxin. But by then, the intellectual climate had changed. The field moved from habitual use to suspicion, and eventually to a near-slogan of “digoxin for nobody.”

What is different now is that the contemporary reappraisal rests not on nostalgia but on new trial evidence interpreted in the context of residual risk despite modern therapy. As reviewed recently by Mandrola, the accumulated signal from the original DIG trial, the newer DIGIT-HF trial, the DECISION trial, and the DECISION withdrawal substudy points in the same direction: digitalis does not appear to be a mortality-revolution drug, but it may reduce worsening heart failure events and hospitalization when added to guideline-directed therapy. The recent Medscape review also highlighted a clinically important pattern: benefit may be greatest in patients with higher heart rate, lower blood pressure, and atrial fibrillation, and withdrawal of tolerated therapy may itself be hazardous. That makes digitalis newly relevant not as a universal solution, but as a targeted tool for selected patients who remain vulnerable despite the “fantastic four” of modern HFrEF treatment.

So the mature conclusion is neither “digoxin for all” nor “digoxin for nobody.” It is digoxin for the right patient, at the right dose, for the right reason, at the right time. And beyond digoxin lies the larger lesson. Clinical medicine should resist slogans because slogans flatten physiology, oversimplify evidence, and invite cycles of enthusiasm, backlash, and rediscovery. To practice well, we must keep several things in mind at once: physiology, pathophysiology, randomized evidence, the limits of observational data, the importance of endpoints, and the lived reality of the patient in front of us. That is how we avoid these recurrent errors of overuse and overcorrection. The history of digitalis, beginning with Withering and still unfinished today, reminds us that medicine advances best when memory, mechanism, and evidence remain in conversation.

You can learn more by reading our e-book or listening to our audiobook

Mykola Iabluchanskyi (Yabluchansky) together with Andriy Yabluchanskiy